Rayner’s clear vision for the future of cataract surgery

Article

Rayner designs and manufactures IOLs and proprietary injection devices for use in cataract surgery. As the first manufacturer of the IOL, they’ve been working with surgeons for longer than anyone.

Rayner designs and manufactures IOLs and proprietary injection devices for use in cataract surgery. As the first manufacturer of the IOL, they’ve been working with surgeons for longer than anyone.

Today, Rayner are bringing new impetus to this focus with the opening of The Ridley Innovation Centre, a new £20million R&D, training and production facility in Worthing, West Sussex, United Kingdom. This IOL production facility has the capability of manufacturing 3 million intraocular lenses each year.

In addition, their new Enterprise Resource Planning (ERP) quality system enables them to trace every lens from source materials to a patient’s eye. What’s more, Rayner is the only IOL manufacturer in the UK and their investment represents commitment to delivering competitive high quality technology from a well-trained UK manufacturing team.

Their mission statement is to “exist to enable surgeons to focus on what matters: improving patient’s sight. We aim to remain at the forefront of innovation, developing clinically superior ophthalmic tools that aid and streamline the surgical process, with the ultimate objective of improving sight and quality of life.”

Furthermore, Rayner’s aim has always been to provide cataract surgeons with high-quality, innovative and simple solutions which enable superior patient outcomes.

New centre

 


The new centre was also designed with the surgeon at its heart to enable training, education and research. Featuring a wet lab, library, training facilities and even a museum on the history of the IOL, this enables Rayner to engage and partner surgeons and academics in new product development.

Testament to this culture is a product pipeline of 11 new products in 3 years planned to transform Rayner into one of the leading manufacturers of IOLs.

Tim Clover, CEO, explains the significance of the new building: “The opening of The Ridley Innovation Centre marks a significant step in what we plan to be an exciting, transformative period of growth ahead of Rayner. This major investment will treble our manufacturing capacity and put us in the best position to support the company’s ambitious business expansion.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.